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BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) is a progressive and
potentially treatable neurodegenerative disease affecting elderly people, characterized by
gait impairment and ventricular enlargement in brain imaging. Similar findings are seen in
some patients with schizophrenia (SCZ).
OBJECTIVE: To determine the prevalence of SCZ among patients suffering from probable
or possible iNPH and the specific effects of comorbid SCZ on the outcome of the
cerebrospinal fluid (CSF) shunting.
METHODS: Allmedical records of the 521 iNPHpatients in theNPH registrywere retrospec-
tively analyzed from 1991 until 2017. The prevalence of comorbidity of SCZ was determined
and compared to that of general aged (≥65 yr) population in Finland.
RESULTS: We identified a total of 16 (3.1%) iNPH patients suffering from comorbid SCZ.
The prevalence of SCZ among the iNPH patients was significantly higher compared to the
general population (3.1% vs 0.9%, P< .001). All iNPH patients with comorbid SCZ were CSF
shunted and 12 (75%) had a clinically verified shunt response 3 to 12mo after the procedure.
The CSF shunt response rate did not differ between patients with and without comorbid
SCZ.
CONCLUSION: SCZ seems to occur 3 times more frequently among iNPH patients
compared to the general aged population in Finland. The outcome of the treatment
was not affected by comorbid SCZ and therefore iNPH patients suffering from comorbid
SCZ should not be left untreated. These results merit validation in other populations. In
addition, further research towards the potential connection between these chronic condi-
tions is warranted.
KEYWORDS: Cohort study, Comorbidity, Normal pressure hydrocephalus, Schizophrenia, Outcome, Prevalence
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I diopathic normal pressure hydrocephalus(iNPH) is a progressive and potentiallytreatable neurodegenerative disease affecting
elderly people and characterized by gait
impairment and ventricular enlargement in
ABBREVIATIONS: Abeta, amyloid beta; CSF,
Cerebrospinal fluid; CT, computed tomography;
DSM-IV, Diagnostic and StatisticalManual ofMental
Disorders 4th edition;HPtau, hyperphosphorylated
tau; ICD-10, International Statistical Classification of
Diseases and Related Health Problems 10th revision;
iNPH, idiopathic normal pressure hydrocephalus;
iNPHGS, iNPH Grading Scale; MMSE, Mini-Mental
State Examination; MRI, magnetic resonance
imaging; NPH, normal pressure hydrocephalus;
SCZ, Schizophrenia; sNPH, secondary normal
pressure hydrocephalus.
computed tomography (CT) or magnetic
resonance imaging (MRI) of the brain,
while cognitive impairment and urinary
incontinence are often present.1-3 The only
available treatment, cerebrospinal fluid (CSF)
shunting, alleviates some the symptoms in the
majority of those affected.4,5 Schizophrenia
(SCZ) is a serious mental disorder with high
heritability characterized by hallucinations,
social withdrawal, and cognitive decline.6 SCZ
is also associated with progressive structural
brain changes, including the enlargement of
lateral ventricles and the reduction of total gray
matter volume.7 In general, the risk of a Finnish
person having SCZ in their lifetime is 0.9%;8 the
Eastern Finnish population exhibiting slightly
higher 1.1% lifetime prevalence.9
iNPH has been associated with different types
of psychiatric manifestations,10-24 ranging from
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apathy to psychotic symptoms,10-23 but SCZ as a comorbid
condition has not been previously systematically analyzed; SCZ
or psychotic symptoms accompanied by iNPH have been
reported infrequently in the literature during the past 4 decades
(Table 1),11,14-24 the majority being case reports.15-18,21-23
However, the latest prospective study indicated an increased
prevalence of iNPH in older patients with SCZ (5/24, 24%) in a
highly selected hospital population.14 The prevalence of psychotic
symptoms or SCZ in patients with iNPH has been estimated to
be low.12,16,20,24
In this study, we aim to determine (1) the prevalence
of SCZ among Eastern Finnish population suffering from
probable/possible iNPH, and (2) the specific effects of comorbid
SCZ on the treatment outcome of CSF shunting.
METHODS
Study Design & Participants
NPH Registry and Tissue Bank
Permission for this research was received from the Research Ethics
Board of the local University Hospital, a hospital that geographi-
cally provides serves neurosurgery to the Eastern Finnish population of
approximately 900 000 inhabitants. The study was conducted according
to the Declaration of Helsinki and all patients provided informed
consent. People suspected to suffer from iNPH in this geographical area
were primarily examined by a neurologist and referred for further neuro-
surgical investigations if the patients exhibited 1 to 3 symptoms possibly
related to NPH (impaired gait, impaired cognition, or urinary conti-
nence) together with enlarged brain ventricles disproportionate to the
size of the sulci of cerebral convexities (Evans’ index > 0.3)2 in CT or
MRI (Figure).
From 1991 until 2010, the NPH protocol included a 24-h intra-
ventricular pressure monitoring and a small right frontal cortical biopsy
from all patients with suspected iNPH. In early 2010, a systematic CSF
sampling from all patients was included and a 3-step prognostic test
protocol was launched. First, a CSF tap test is performed to all patients
with suspected iNPH, where at least 20% improvement in gait speed in
repeated 10-m tests is considered as a positive result. In the second phase,
those with a negative tap test undergo a lumbar infusion test, where
pathological findings (such as conductance ≤ 10)3,25 are considered as a
positive result. In the third step, participants with a negative finding in
both of the abovementioned tests undergo a 24-hmonitoring of intraven-
tricular pressure. Similarly, as of 2010, brain biopsies are only acquired
from participants who undergo intraventricular pressure monitoring or
the CSF shunt surgery.
Study Population and Study Design
Between January 1991 and February 2017 (26 yr), 892 consecutive
patients with suspected iNPH were included to the registry (Figure).
Altogether 521 (58%) participants were identified to suffer from
probable or possible iNPH and 371 (42%) participants were identified
as unlikely to have iNPH (instead having, for example secondary NPH
(sNPH)).1,2 All medical records, prescriptions and comorbidities of
probable/possible and unlikely iNPH patients were retrospectively and
systematically examined for the diagnosis of SCZ.
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PREVALENCE OF SCHIZOPHRENIA IN INPH
FIGURE. Flowchart of the study population. aImpairment of gait, cognition or urinary incontinence. bEvans’ index > .3 in computed tomography
or magnetic resonance imaging;2 cRelkin et al, 2005;1 dMori et al, 2012.2 Abbreviations: iNPH, idiopathic normal-pressure hydrocephalus; sNPH,
secondary NPH; CSF, cerebrospinal fluid.
General Population Control Group
Health 2000 was a general health examination survey based on a
nationally representative sample of 8028 people aged 30 yr and older,
including a sample of 2157 subjects aged 65 yr or older.8 Psychotic
disorders were screened using information from nationwide health care
registers and self-reported symptoms as described in detail elsewhere,8
and DSM-IV diagnoses were confirmed by using the Structured Clinical
Interview for DSM-IV and/or information on psychiatric symptoms
from medical records of all lifetime psychiatric treatment contacts.8 The
prevalence of SCZ in the oldest age group has been reported previously.8
Here, the actual numbers were utilized for a formal statistical comparison
of the prevalence of SCZ in patients with iNPH compared to the general
population.
Outcome Indicators
To assess the severity of the characterizing symptoms of iNPH,
a modified Finnish version of the 12-point iNPH Grading Scale
(iNPHGS) was used (Table 2).26 iNPHGS is a clinician-rated scale
to separately estimate the severity of each of the triad symptoms with
a scoring based on interviews with the patients or their caregivers
and observations by the physician.26 Lower scores represent less severe
symptoms.26 It has been estimated that even a reduction in the iNPHGS
by a single point results in a clinically observable improvement in the
patient’s condition.27 Similarly, a clinically verified shunt response was
assessed by a neurosurgeon 3 to 12 mo postoperatively at the outpa-
tient clinic.28 The patient was classified to be nonresponsive to the CSF
shunt if no improvement in the core symptoms (gait, cognition, and
urinary incontinence) was detected.28 Cognition was evaluated by using
the Mini-Mental State Examination (MMSE).29 MMSE ranges from 0
to 30, with lower scores indicating a greater cognitive decline.29
Frontal Cortical Biopsy
Biopsy needles or forceps were used to obtain one to three cylindrical
frontal cortical brain biopsies, of 3 to 7 mm in length and 2 to 5 mm
in width, prior the insertion of the ventricular catheter of the CSF shunt
(adjacent to the coronal suture of the skull and approximately 3 cm from
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TABLE 2. Comparison Between 521 Study ParticipantsWith andWithout Schizophrenia
Schizophrenia (n= 16) no schizophrenia (n= 505)
Variables
Mean or
number of
participants
SD
or
%
Number of
observations
if anymissing
data
Mean or
number of
participants
SD
or
%
number of
observations
if anymissing
data
Test
statistics P-value
CSF Shunting surgery
CSF shunt surgery was performed (yes) 16 100 489 97 >.99c
Favorable clinical outcome 3-12 mo postoperatively (yes) 12 75 407 83 .32c
Favorable INPHGS outcome (yes)
3 mo postoperatively 4 40 10 104 48 219 .75c
12 mo postoperatively 2 50 4 87 50 173 >.99c
Characteristics
Age (at referral to the neurosurgical department) 65 5.3 73 7.2 Z= −4.22 < .001a
Sex (Female) 8 50 267 53 χ 2 = .05 >.99b
History of INPH INPH-related symptoms
Impairment of gait 13 81 476 94 .07c
Urinary incontinence or urge 9 56 374 74 .15c
Impaired cognition 11 69 411 81 .20c
Full triad 5 31 304 60 χ 2 = 5.39 .035b
Onset of iNPH-related symptoms 15 499 χ 2 = 3.17 .11b
Onset a year or less from the referral 10 66 217 43
Onset more than a year from the referral 5 34 282 57
First symptom of iNPH 494
Impairment of gait or imbalance 9 56 265 54 χ 2 = .09 .81b
Cognition impairment 3 19 124 25 .77c
Vertigo 2 13 53 11 .68c
Urinary incontinence or urge 1 6 27 5 .59c
Other 1 6 25 5 .57c
Severity of INPH-related symptoms preoperatively
INPHGS total score (0-12) 6.0 2.1 10 6.2 2.8 247 Z = −.32 .75a
Cognition impairment (MMSE score, 0-30) 20 4.1 13 22 4.6 429 Z = −.67 .10a
Comorbidity
Presence of Abeta or HPtau found in the frontal cortical biopsy 7 44 221 45 490 χ 2 = .01 >.99b
ABBREVIATIONS: iNPH, idiopathic normal pressure hydrocephalus; iNPHGS, iNPH Grading Scale; MMSE, Mini-Mental State Examination; CSF, Cerebrospinal fluid.
LEGEND: Statistically significant difference (P < .05) is bolded. aMann–Whitney U test; bPearson chi-square test cFisher’s exact test.
the midline).28,30 The presence of hyperphosphorylated tau (HPtau) and
amyloid-beta (Abeta) were assessed from all samples by a neuropathol-
ogist by using light microscopy (Table 2).31
Statistics
The data were analyzed by using the Statistical Package for Social
Sciences (SPSS 19 for Windows, Version 19.0. IBM Corp, Armonk,
New York). Pearson’s Chi-square test or Fisher’s exact test was used in
multiple comparisons to estimate group differences in nominal variables
and theMann–WhitneyU test for continuous variables, respectively. The
Mann–Whitney U test was used due to the nonnormal distribution of
continuous variables. To test the difference in the prevalence of SCZ
between the studied patients and the general population, the cases of
SCZ were weighted by the amount of observations in both populations
and compared. All tests for significance were 2-sided, with probabilities
of < .05 accepted as statistically significant.
RESULTS
Sixteen (3.1%) participants with probable or possible iNPH
were identified to have comorbid SCZ, the most common
SCZ subtype being residual SCZ (25%; Figure, Table 3). All
observed SCZ subtypes, 5-yr occurrences of SCZ, and the
prognostic/ancillary tests performed on to patients suffering from
SCZ prior to the CSF shunting, are presented in (Table 3). The
observed prevalence of comorbid SCZ among iNPH patients was
significantly higher compared to the age-weighted control sample
set from the general population (3.1% vs 0.9%, absolute risk
difference 2.2%; Fisher’s exact test, P < .001; Table 4).
All participants with SCZ were CSF shunted and 12 (75%)
of them had a favorable clinical outcome assessed by a neuro-
surgeon 3 to 12 mo after the procedure (Table 2). Favorable
outcome rates, measured by INPHGS or assessed by a neuro-
surgeon, did not differ statistically between iNPH patients with
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TABLE 3. Characteristics of 16 ParticipantsWith Schizophrenia
Number of subjects with
schizophrenia (% of total sample)
Number of participants with iNPH
(% of participants with SCZ)
SCZ subtypes (ICD-10)
Residual schizophrenia (F20.5) 4 (25)
Paranoid schizophrenia (F20.0) 3 (19)
Chronic schizophrenia (F20) 2 (13)
Catatonic schizophrenia (F20.2) 1 (6)
Hebephrenic schizophrenia (F20.1) 1 (6)
Schizophrenia, unspecified (F20.9) 1 (6)
SCZ without subtype specification 4 (25)
5-yr occurrence of SZC in the NPH registry
1991-1995 2 (13) 42 (5)
1995-2000 2 (13) 48 (4)
2000-2005 1 (6) 85 (1)
2005-2010 2 (13) 114 (2)
2010-2015 6 (37) 162 (4)
2015 3 (18) 56 (5)
Prognostics and ancillary tests used preliminary to CSF shunt
CSF tap test 7 (44)
CSF tap & infusion tests 2 (12)
ICP monitoring 7 (44)
ABBREVIATIONS: iNPH, idiopathic normal pressurehydrocephalus; CSF, Cerebrospinal fluid; ICP, Intracranial pressure; SCZ, Schizophrenia; ICD-10, International Statistical Classification
of Diseases and Related Health Problems 10th revision.
TABLE 4. Comparison of Prevalence of Schizophrenia Between NPH Registry and a Sample From the General Population
Population Comparisons
NPH Registry
n= 521
Age-weighteda Sample of
65 yr olds or older from the
general population n= 746 711
Absolute risk
difference
Fisher’s exact test
P-value
Schizophrenia Yes (%) 16 (3.1) 6835 (.9) 2.2% < .001
No (%) 505 (96.9) 746 711 (99.1)
ABBREVIATIONS: NPH, Normal pressure hydrocephalus; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 4th edition.
Legend: aWeighted by age using SUDAAN-script to take into account the increased mortality8 without weighting the general population was the size of 2157 of which 17 people
had schizophrenia.8In the general population sample,8 diagnoses of schizophrenia (DSM-IV diagnoses) were confirmed by using the Structured Clinical Interview for DSM-IV and/or
information on psychiatric symptoms from themedical records of all lifetime psychiatric treatment contacts,8 while in our study, the diagnosis of schizophrenia was retrospectively
obtained by systematically examining all the medical records, prescriptions and comorbidities of the study population. Statistically significant difference (P < .05) is bolded.
and without comorbid SCZ (Table 2). Patients with comorbid
SCZ were referred to the neurosurgical department at a signif-
icantly younger age than those without SCZ (Mann–Whitney
U-test, P < .001) and exhibited less frequently the triad of core
symptoms associated with iNPH (31% vs 60%, Fisher’s exact test,
P = .035; Table 2). Otherwise, the onset and first symptoms, the
severity of iNPH-related symptoms and the cognitive impairment
of patients with comorbid SCZ were similar to other iNPH
patients (Table 2). There was no difference in the prevalence of
Alzheimer’s disease-related pathology (Abeta or HPtau) in the
frontal cortical biopsy between the patient groups (44% vs 45%;
Table 2).
DISCUSSION
Interpretation
SCZ was observed to occur 3 times more frequently among
the iNPH patients compared to the general aged population in
Finland (Table 4), and the number of patients with comorbid
SCZ within the NPH registry seems to increase over time
(Table 3). The increased awareness of iNPH24 or the change in
the data collection method (Figure ) may partly explain the differ-
ences in the number of people with SCZ referred to the neurosur-
gical department and recorded to the registry (Figure andTable 3).
As people with SCZ have a higher mortality rate32 and because
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iNPH affects mainly the elderly population,1-3 the prevalence of
comorbid SCZ among the people with iNPH could be underes-
timated. A recent study14 hypothesized that the increased preva-
lence of iNPH in people with SCZ could partly be explained by
the vascular risk factors33 that are also common in patients with
iNPH although their exact role in the pathogenesis of iNPH is yet
to be determined.34,35 In 2010, the brief research history of iNPH
and SCZ was reviewed in a book chapter on secondary SCZ;24
two studies36,37 suggested a common pathology between sNPH
and SCZ, and the 2 conditions portrayed similar abnormalities in
CSF dynamics in isotope cisternography. However, there was no
further replication of these studies.
Identifying iNPH in a person with SCZ is challenging. Even
missed diagnoses are possible since ventriculomegaly seen in
iNPH could be ignored as the increased volume of ventricles is
common in elderly people with SCZ.24,38 The largely unknown
origin of structural brain abnormalities in SCZ has been
suggested to possibly reflect the neurodevelopment of SCZ,38,39
although the progressive enlargement of lateral ventricles can
also occur after the onset of SCZ.7 These structural changes
have also been associated with long-term antipsychotic and
benzodiazepine use in people with SCZ.40 Similarly, a part of
the clinical appearance of iNPH, the impairment of gait or
cognition, could easily be attributed to the side effects of long-
standing antipsychotic treatment, or to the normal and highly
varying progression/symptomology of SCZ, and thus lead to
a missed diagnosis.14,24 It is important to acknowledge that if
an aged person with SCZ exhibits progressive disturbances in
gait, cognition, or urinary incontinence that cannot be entirely
attributed to the SCZ or its treatment, and if the symptoms are
accompanied by ventriculomegaly, iNPH should be considered
when sNPH is excluded.1,2,14,23 In our study, the clinical charac-
teristics of iNPH were nearly equal in the participants with and
without comorbid SCZ, but on average, those with SCZ were
expressing the classical symptom triad of iNPH less frequently
and were referred to the neurosurgical investigations younger
than their counterparts (Table 2). A previous study described
a similar case of a iNPH patient with comorbid SCZ.15It
could be hypothesized that coexisting SCZ or its treatment
may affect the onset and possibly the progression of iNPH.
Otherwise, no further differences were identified in the clinical
characteristics.
Comorbid SCZ did not have any effect on the CSF shunt
response or the overall treatment outcome between the 2
groups. The observed shunt response rates were in line with
the results previously reported in literature.5 Therefore, iNPH
patients suffering from comorbid SCZ should not be left
untreated. In our study, due to the limited number of partic-
ipants with SCZ, the accuracy of different prognostic tests
applied prior to the CSF shunting in participants with and
without comorbid SCZ and cannot be fully estimated. Based on
clinical experience, we suggest that the prognostic tests should
be performed in the same way to the patients with and without
comorbid SCZ.
Strengths and Limitations
The strengths of this study include large representative
population samples from both the people with iNPH and
the general aged population. In addition, to the best of our
knowledge, ours are the first published findings on the preva-
lence of SCZ in the iNPH population. Due to the cross-sectional
setting in the analyses, we are unable to draw direct conclusions
on the causal relationships between iNPH and SCZ. The effect
of the CSF shunt on the psychotic symptoms in iNPH patients
with comorbid SCZ would have further strengthened the study.
The diagnosis of SCZ was retrospectively obtained by systemati-
cally examining all the medical records, prescriptions and comor-
bidities of the study population instead of a psychiatric interview.
The participants that were admitted before the year 2008 to
the NPH registry were gathered retrospectively at the time. The
clinical outcome was not evaluated with INPHGS from all partic-
ipants. Diagnosis date of SCZ was not captured in our study.
However, it was, in all affected, set decades before any suspicion
of iNPH. Two different diagnostic guidelines for iNPH exist.1,2
As symptomatic SCZ patients might be investigated by imaging
studies more frequently than older patients without SCZ, an age
bias is possible.
CONCLUSION
In summary, SCZ seems to occur 3 times more frequently
among iNPHpatients as compared to the general aged population
in Finland. Still, the treatment outcome is not affected by
comorbid SCZ and therefore iNPH patients suffering from
comorbid SCZ should not be left untreated. These results merit
validation in other populations. In addition, further research
towards the possible shared underlying pathological mechanisms
of these 2 long-lasting conditions is needed.
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COMMENT
T his study of iNPH in schizophrenia patients performed in EasternFinland, a reliable health care system environment for such a
study, indicates several interesting findings that have remained sidelined
until now. In addition to the 3 times higher prevalence of iNPH
among schizophrenic patients, the similarity of clinical and radiological
phenomena makes the differentiation of the two conditions regarding
effect of shunting and prognosis rather difficult. This is the first
systematic approach to identify schizophrenic patients that can benefit
of shunting (they are usually younger) and the study attempts to assess
the outcome that can be expected; in fact, these patients benefitted from
shunting at the same rate as general iNPH patients. We believe that with
these presented data that we have to consider initial, the relation of iNPH
to some of the manifestations of schizophrenia will attract attention and
we will improve its understanding.
Madoka Nakajima
Tokyo, Japan
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